Form 4: Castle Biosciences Director Bradley Cole Reports Stock Transaction
SEC Form 4
Director Bradley Cole of Castle Biosciences reports the vesting of restricted stock units and subsequent acquisition of common stock on May 25, 2024.
Summary
- On May 25, 2024, Bradley Cole, a director at Castle Biosciences, had 8,636 Restricted Stock Units (RSUs) vest.
- Each RSU represents the right to receive one share of Castle Biosciences' Common Stock.
- Upon vesting, Cole acquired 8,636 shares of Common Stock.
- Following the transaction, Cole directly owns 13,291 shares of Castle Biosciences' Common Stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Positives
- The vesting of RSUs indicates that performance milestones or time-based conditions have been met.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into insider transactions, allowing investors to monitor the buying and selling activity of company insiders.
Stakeholder Impact
- Shareholders can use this information to understand insider activity and sentiment towards the company's stock.
Key Dates
| Date | Description |
|---|---|
| 05/25/2024 | Date of transaction: RSUs vested and Common Stock acquired. |
| 05/29/2024 | Date of report filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.